DiaMedica Therapeutics (DMA) Reaches New 1-Year High at $8.50
DiaMedica Therapeutics Inc (CVE:DMA)’s share price hit a new 52-week high on Thursday . The stock traded as high as C$8.50 and last traded at C$6.80, with a volume of 34000 shares changing hands. The stock had previously closed at C$0.35.
DiaMedica Therapeutics (CVE:DMA) last issued its quarterly earnings results on Wednesday, August 29th. The company reported C($0.03) earnings per share for the quarter, missing the consensus estimate of C($0.01) by C($0.02).
TRADEMARK VIOLATION NOTICE: “DiaMedica Therapeutics (DMA) Reaches New 1-Year High at $8.50” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2018/11/15/diamedica-therapeutics-dma-reaches-new-1-year-high-at-8-50.html.
DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications.
Featured Article: How is a Moving Average Calculated?
Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.